| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammary Glands, Animal | 13 | 2016 | 47 | 3.390 |
Why?
|
| Macaca fascicularis | 37 | 2019 | 397 | 2.820 |
Why?
|
| Estradiol | 9 | 2018 | 128 | 1.890 |
Why?
|
| Animals | 78 | 2020 | 7463 | 1.830 |
Why?
|
| Whole-Body Irradiation | 7 | 2019 | 50 | 1.710 |
Why?
|
| Macaca mulatta | 17 | 2019 | 285 | 1.560 |
Why?
|
| Isoflavones | 5 | 2013 | 69 | 1.460 |
Why?
|
| Soybean Proteins | 5 | 2016 | 68 | 1.430 |
Why?
|
| Medroxyprogesterone Acetate | 8 | 2012 | 93 | 1.390 |
Why?
|
| Endometrium | 9 | 2016 | 175 | 1.380 |
Why?
|
| Postmenopause | 12 | 2013 | 414 | 1.370 |
Why?
|
| Radiation Injuries, Experimental | 6 | 2019 | 34 | 1.330 |
Why?
|
| Brain Injuries | 2 | 2018 | 93 | 1.130 |
Why?
|
| Receptors, Progesterone | 8 | 2015 | 63 | 1.080 |
Why?
|
| Breast Neoplasms | 8 | 2015 | 761 | 1.070 |
Why?
|
| Female | 64 | 2019 | 19920 | 1.030 |
Why?
|
| Breast | 4 | 2009 | 61 | 1.010 |
Why?
|
| Estrogens, Conjugated (USP) | 9 | 2013 | 128 | 1.000 |
Why?
|
| Soybeans | 4 | 2013 | 26 | 0.970 |
Why?
|
| Estrogen Replacement Therapy | 5 | 2012 | 188 | 0.960 |
Why?
|
| Sexual Maturation | 4 | 2016 | 25 | 0.960 |
Why?
|
| Monkey Diseases | 3 | 2016 | 16 | 0.960 |
Why?
|
| Diet | 6 | 2016 | 386 | 0.940 |
Why?
|
| Extracellular Matrix | 4 | 2018 | 245 | 0.900 |
Why?
|
| Brain | 5 | 2020 | 950 | 0.900 |
Why?
|
| Gamma Rays | 3 | 2019 | 25 | 0.860 |
Why?
|
| Estrogen Receptor alpha | 7 | 2015 | 50 | 0.860 |
Why?
|
| Uterus | 6 | 2015 | 93 | 0.830 |
Why?
|
| Ovariectomy | 16 | 2018 | 149 | 0.820 |
Why?
|
| Cell Proliferation | 12 | 2019 | 598 | 0.810 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 493 | 0.800 |
Why?
|
| Placenta | 4 | 2013 | 74 | 0.720 |
Why?
|
| Endometrial Neoplasms | 2 | 2011 | 45 | 0.720 |
Why?
|
| Vagina | 2 | 2012 | 57 | 0.710 |
Why?
|
| Radiation Injuries | 3 | 2017 | 72 | 0.680 |
Why?
|
| Progesterone | 3 | 2009 | 95 | 0.670 |
Why?
|
| Endometriosis | 2 | 2018 | 98 | 0.650 |
Why?
|
| Contraceptives, Oral | 2 | 2008 | 22 | 0.640 |
Why?
|
| Immunohistochemistry | 10 | 2016 | 532 | 0.630 |
Why?
|
| Fibronectins | 1 | 2018 | 36 | 0.630 |
Why?
|
| Receptors, Estrogen | 8 | 2016 | 103 | 0.620 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 63 | 0.620 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 92 | 0.600 |
Why?
|
| Gene Expression | 6 | 2018 | 333 | 0.600 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 156 | 0.580 |
Why?
|
| Tamoxifen | 4 | 2014 | 56 | 0.580 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2020 | 68 | 0.580 |
Why?
|
| Norpregnenes | 5 | 2013 | 16 | 0.570 |
Why?
|
| Phytoestrogens | 2 | 2016 | 17 | 0.560 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 51 | 0.560 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 93 | 0.550 |
Why?
|
| Decidua | 1 | 2016 | 18 | 0.550 |
Why?
|
| Menopause | 3 | 2011 | 92 | 0.530 |
Why?
|
| Epilepsy | 1 | 2017 | 82 | 0.530 |
Why?
|
| Random Allocation | 9 | 2018 | 220 | 0.520 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 26 | 0.510 |
Why?
|
| Estrogen Antagonists | 2 | 2012 | 16 | 0.510 |
Why?
|
| Cell Differentiation | 2 | 2016 | 468 | 0.480 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 311 | 0.480 |
Why?
|
| Cognition Disorders | 2 | 2015 | 384 | 0.460 |
Why?
|
| Puberty | 1 | 2013 | 7 | 0.450 |
Why?
|
| Estrogens | 4 | 2013 | 167 | 0.440 |
Why?
|
| Syndecan-1 | 3 | 2012 | 11 | 0.430 |
Why?
|
| Male | 29 | 2019 | 19161 | 0.430 |
Why?
|
| Genistein | 2 | 2009 | 14 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2017 | 1428 | 0.430 |
Why?
|
| Progestins | 2 | 2013 | 20 | 0.420 |
Why?
|
| Cognition | 1 | 2016 | 553 | 0.410 |
Why?
|
| Ki-67 Antigen | 6 | 2015 | 26 | 0.410 |
Why?
|
| Dose-Response Relationship, Radiation | 6 | 2019 | 78 | 0.410 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2011 | 11 | 0.390 |
Why?
|
| Insulin Resistance | 4 | 2020 | 461 | 0.390 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 322 | 0.390 |
Why?
|
| Sentinel Surveillance | 1 | 2011 | 11 | 0.380 |
Why?
|
| Apoptosis | 4 | 2013 | 352 | 0.380 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 41 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 261 | 0.370 |
Why?
|
| Tracheostomy | 1 | 2011 | 30 | 0.370 |
Why?
|
| Trachea | 1 | 2011 | 53 | 0.370 |
Why?
|
| Bacterial Infections | 1 | 2011 | 52 | 0.370 |
Why?
|
| Humans | 30 | 2019 | 31981 | 0.360 |
Why?
|
| Endometrial Hyperplasia | 2 | 2013 | 14 | 0.350 |
Why?
|
| Androgens | 1 | 2009 | 29 | 0.330 |
Why?
|
| Mammography | 1 | 2009 | 42 | 0.330 |
Why?
|
| Soy Foods | 1 | 2009 | 7 | 0.330 |
Why?
|
| Selective Estrogen Receptor Modulators | 4 | 2013 | 34 | 0.330 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 23 | 0.330 |
Why?
|
| Testosterone | 1 | 2009 | 47 | 0.330 |
Why?
|
| RNA, Messenger | 5 | 2016 | 507 | 0.330 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 4 | 0.330 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 4 | 0.330 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2008 | 6 | 0.330 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 638 | 0.330 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 34 | 0.320 |
Why?
|
| Mice | 15 | 2020 | 2472 | 0.320 |
Why?
|
| Contraceptive Agents, Female | 1 | 2008 | 15 | 0.320 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2008 | 6 | 0.320 |
Why?
|
| Pyrrolidines | 1 | 2008 | 12 | 0.320 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 124 | 0.320 |
Why?
|
| Receptors, Androgen | 1 | 2009 | 46 | 0.320 |
Why?
|
| Homeostasis | 3 | 2019 | 132 | 0.310 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2008 | 20 | 0.310 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 64 | 0.300 |
Why?
|
| Transcription, Genetic | 4 | 2019 | 137 | 0.300 |
Why?
|
| Social Behavior | 1 | 2007 | 65 | 0.290 |
Why?
|
| Disease Models, Animal | 9 | 2015 | 1017 | 0.290 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 160 | 0.290 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2012 | 27 | 0.290 |
Why?
|
| Heart | 2 | 2018 | 179 | 0.270 |
Why?
|
| Hormone Replacement Therapy | 6 | 2013 | 88 | 0.270 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 260 | 0.260 |
Why?
|
| Body Weight | 5 | 2016 | 310 | 0.250 |
Why?
|
| Motor Activity | 1 | 2007 | 325 | 0.250 |
Why?
|
| Pregnancy | 6 | 2013 | 994 | 0.240 |
Why?
|
| Proliferating Cell Nuclear Antigen | 3 | 2009 | 30 | 0.240 |
Why?
|
| Obesity | 3 | 2020 | 1176 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 57 | 0.240 |
Why?
|
| Prostatic Neoplasms | 3 | 2015 | 470 | 0.230 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Organ Size | 4 | 2018 | 210 | 0.220 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 1125 | 0.220 |
Why?
|
| Signal Transduction | 5 | 2014 | 682 | 0.220 |
Why?
|
| Histocytochemistry | 3 | 2013 | 30 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Mice, Knockout | 5 | 2020 | 442 | 0.220 |
Why?
|
| Protein Isoforms | 2 | 2020 | 57 | 0.220 |
Why?
|
| Indoles | 2 | 2013 | 56 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Genes, erbB-2 | 2 | 2012 | 5 | 0.210 |
Why?
|
| Receptors, Calcitriol | 2 | 2012 | 9 | 0.210 |
Why?
|
| Time Factors | 6 | 2019 | 2151 | 0.210 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2012 | 27 | 0.210 |
Why?
|
| Receptors, Steroid | 2 | 2012 | 7 | 0.200 |
Why?
|
| Ovary | 3 | 2011 | 58 | 0.200 |
Why?
|
| Energy Metabolism | 2 | 2020 | 148 | 0.200 |
Why?
|
| Prostate | 2 | 2015 | 67 | 0.200 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2014 | 12 | 0.190 |
Why?
|
| Lactalbumin | 2 | 2012 | 10 | 0.190 |
Why?
|
| Caseins | 2 | 2012 | 14 | 0.190 |
Why?
|
| Coronary Vessels | 2 | 2012 | 160 | 0.190 |
Why?
|
| Pterocarpans | 2 | 2011 | 4 | 0.190 |
Why?
|
| Models, Animal | 4 | 2013 | 164 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 6 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 941 | 0.170 |
Why?
|
| Hematopoietic System | 1 | 2019 | 3 | 0.170 |
Why?
|
| Estrogen Receptor beta | 2 | 2009 | 12 | 0.170 |
Why?
|
| Myocardium | 2 | 2018 | 186 | 0.160 |
Why?
|
| Immunity | 1 | 2019 | 22 | 0.160 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 401 | 0.160 |
Why?
|
| Diastole | 1 | 2018 | 96 | 0.160 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 42 | 0.160 |
Why?
|
| Skin Neoplasms | 2 | 2014 | 214 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 90 | 0.160 |
Why?
|
| Cell Line | 4 | 2019 | 435 | 0.160 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 37 | 0.160 |
Why?
|
| Blood Cells | 1 | 2018 | 9 | 0.150 |
Why?
|
| Monocytes | 1 | 2019 | 126 | 0.150 |
Why?
|
| Placebos | 2 | 2008 | 63 | 0.150 |
Why?
|
| Administration, Oral | 2 | 2009 | 182 | 0.150 |
Why?
|
| Adiposity | 1 | 2019 | 199 | 0.150 |
Why?
|
| Cross-Over Studies | 2 | 2008 | 93 | 0.150 |
Why?
|
| Rats | 4 | 2015 | 1596 | 0.150 |
Why?
|
| Macrophages | 2 | 2018 | 191 | 0.150 |
Why?
|
| Microvessels | 1 | 2017 | 25 | 0.150 |
Why?
|
| DNA Damage | 1 | 2018 | 98 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2008 | 463 | 0.140 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 101 | 0.140 |
Why?
|
| Mice, Transgenic | 5 | 2019 | 261 | 0.140 |
Why?
|
| Cytokines | 1 | 2018 | 255 | 0.140 |
Why?
|
| Receptors, Opioid | 1 | 2016 | 12 | 0.140 |
Why?
|
| Calcium | 1 | 2018 | 307 | 0.140 |
Why?
|
| Chemokines | 1 | 2016 | 35 | 0.140 |
Why?
|
| Toxicology | 2 | 2013 | 6 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 120 | 0.140 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 80 | 0.140 |
Why?
|
| Mutation, Missense | 2 | 2014 | 50 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2016 | 142 | 0.130 |
Why?
|
| Atherosclerosis | 2 | 2013 | 767 | 0.130 |
Why?
|
| Logistic Models | 2 | 2009 | 781 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2016 | 189 | 0.130 |
Why?
|
| Mammary Glands, Human | 2 | 2015 | 15 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 197 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2016 | 130 | 0.130 |
Why?
|
| Middle Aged | 5 | 2016 | 11845 | 0.130 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2013 | 25 | 0.130 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 10 | 0.130 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 21 | 0.130 |
Why?
|
| Inflammation | 2 | 2016 | 530 | 0.130 |
Why?
|
| Luminescent Proteins | 1 | 2015 | 26 | 0.130 |
Why?
|
| Rats, Inbred F344 | 1 | 2015 | 133 | 0.130 |
Why?
|
| Myometrium | 2 | 2014 | 11 | 0.130 |
Why?
|
| Citric Acid | 1 | 2014 | 6 | 0.130 |
Why?
|
| Primates | 2 | 2012 | 104 | 0.130 |
Why?
|
| Hirudins | 1 | 2014 | 19 | 0.120 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 48 | 0.120 |
Why?
|
| Epithelial Cells | 3 | 2013 | 138 | 0.120 |
Why?
|
| Platelet Aggregation | 1 | 2014 | 21 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2019 | 1267 | 0.120 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 45 | 0.120 |
Why?
|
| Myoblasts, Skeletal | 1 | 2015 | 19 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2014 | 39 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2015 | 49 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2015 | 103 | 0.120 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 44 | 0.120 |
Why?
|
| Muscle, Skeletal | 2 | 2017 | 518 | 0.120 |
Why?
|
| Child | 4 | 2019 | 2433 | 0.120 |
Why?
|
| Heparin | 1 | 2014 | 74 | 0.120 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 70 | 0.120 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2015 | 65 | 0.120 |
Why?
|
| DNA Adducts | 1 | 2014 | 12 | 0.120 |
Why?
|
| Risk | 1 | 2015 | 319 | 0.120 |
Why?
|
| Gene Deletion | 1 | 2014 | 66 | 0.120 |
Why?
|
| Glucose | 1 | 2015 | 174 | 0.120 |
Why?
|
| Radiography | 1 | 2015 | 377 | 0.110 |
Why?
|
| Urethra | 1 | 2015 | 102 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2015 | 180 | 0.110 |
Why?
|
| Growth Hormone | 2 | 2010 | 13 | 0.110 |
Why?
|
| Radiation Pneumonitis | 1 | 2013 | 4 | 0.110 |
Why?
|
| Mast Cells | 1 | 2013 | 11 | 0.110 |
Why?
|
| Rats, Inbred Strains | 1 | 2013 | 45 | 0.110 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 47 | 0.110 |
Why?
|
| Lidocaine | 1 | 2013 | 18 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 52 | 0.110 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2013 | 24 | 0.110 |
Why?
|
| Cardiovascular Agents | 1 | 2013 | 23 | 0.110 |
Why?
|
| Toxicity Tests | 1 | 2013 | 13 | 0.110 |
Why?
|
| Adenosine | 1 | 2013 | 59 | 0.110 |
Why?
|
| Heart Arrest | 1 | 2013 | 38 | 0.110 |
Why?
|
| Pathology | 1 | 2013 | 17 | 0.110 |
Why?
|
| Premenopause | 2 | 2012 | 42 | 0.110 |
Why?
|
| Frameshift Mutation | 1 | 2012 | 6 | 0.110 |
Why?
|
| Receptors, Thyrotropin-Releasing Hormone | 1 | 2012 | 1 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 209 | 0.110 |
Why?
|
| Receptors, Thyrotropin | 1 | 2012 | 2 | 0.110 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2012 | 2 | 0.110 |
Why?
|
| Animals, Wild | 1 | 2012 | 2 | 0.110 |
Why?
|
| Animals, Zoo | 1 | 2012 | 2 | 0.110 |
Why?
|
| Primate Diseases | 1 | 2012 | 3 | 0.110 |
Why?
|
| Body Composition | 1 | 2015 | 396 | 0.110 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2012 | 4 | 0.110 |
Why?
|
| Cell Transformation, Viral | 1 | 2012 | 8 | 0.110 |
Why?
|
| Metagenome | 1 | 2012 | 5 | 0.110 |
Why?
|
| Reperfusion Injury | 1 | 2013 | 49 | 0.110 |
Why?
|
| Reproduction | 1 | 2012 | 12 | 0.110 |
Why?
|
| Receptors, LDL | 1 | 2013 | 65 | 0.100 |
Why?
|
| DDT | 1 | 2012 | 2 | 0.100 |
Why?
|
| DNA | 1 | 2014 | 227 | 0.100 |
Why?
|
| Drug Combinations | 2 | 2013 | 95 | 0.100 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2012 | 4 | 0.100 |
Why?
|
| Risk Factors | 3 | 2012 | 3867 | 0.100 |
Why?
|
| Intestines | 1 | 2012 | 64 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2012 | 94 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 286 | 0.100 |
Why?
|
| Aggression | 2 | 2012 | 30 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 74 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 148 | 0.100 |
Why?
|
| Skin | 1 | 2014 | 210 | 0.100 |
Why?
|
| Lactation | 1 | 2011 | 15 | 0.100 |
Why?
|
| Choristoma | 1 | 2011 | 17 | 0.100 |
Why?
|
| Cyclooxygenase 1 | 1 | 2011 | 22 | 0.100 |
Why?
|
| PPAR gamma | 2 | 2008 | 46 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 71 | 0.100 |
Why?
|
| Biological Availability | 1 | 2011 | 21 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 47 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2011 | 3523 | 0.100 |
Why?
|
| Bacteriological Techniques | 1 | 2011 | 17 | 0.100 |
Why?
|
| Vitamin D | 1 | 2012 | 183 | 0.090 |
Why?
|
| Betapapillomavirus | 1 | 2010 | 1 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2013 | 218 | 0.090 |
Why?
|
| Age Factors | 2 | 2011 | 1191 | 0.090 |
Why?
|
| Skin Diseases, Viral | 1 | 2010 | 4 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 95 | 0.090 |
Why?
|
| Data Collection | 1 | 2011 | 180 | 0.090 |
Why?
|
| Ethinyl Estradiol | 1 | 2010 | 7 | 0.090 |
Why?
|
| Aged | 3 | 2016 | 10332 | 0.090 |
Why?
|
| Ligaments | 1 | 2010 | 13 | 0.090 |
Why?
|
| Janus Kinase 2 | 1 | 2010 | 6 | 0.090 |
Why?
|
| Acute Disease | 1 | 2011 | 253 | 0.090 |
Why?
|
| Tyrosine | 1 | 2010 | 23 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2010 | 39 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2011 | 188 | 0.090 |
Why?
|
| Hippocampus | 1 | 2011 | 171 | 0.090 |
Why?
|
| Molecular Structure | 1 | 2009 | 59 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 65 | 0.090 |
Why?
|
| Drug Antagonism | 1 | 2009 | 1 | 0.080 |
Why?
|
| Women's Health | 1 | 2011 | 236 | 0.080 |
Why?
|
| Dietary Proteins | 1 | 2009 | 56 | 0.080 |
Why?
|
| Cyclohexenes | 1 | 2009 | 12 | 0.080 |
Why?
|
| Vinyl Compounds | 1 | 2009 | 8 | 0.080 |
Why?
|
| Carcinogens | 1 | 2009 | 33 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2009 | 65 | 0.080 |
Why?
|
| Cricetulus | 1 | 2008 | 12 | 0.080 |
Why?
|
| Diet Surveys | 1 | 2009 | 57 | 0.080 |
Why?
|
| Cricetinae | 1 | 2008 | 39 | 0.080 |
Why?
|
| Adult | 5 | 2019 | 9340 | 0.080 |
Why?
|
| CpG Islands | 1 | 2008 | 45 | 0.080 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2008 | 33 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2013 | 62 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 90 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 765 | 0.080 |
Why?
|
| Blood Cell Count | 2 | 2019 | 28 | 0.080 |
Why?
|
| Prolactin | 1 | 2008 | 9 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 94 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 878 | 0.080 |
Why?
|
| PPAR alpha | 1 | 2008 | 29 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2016 | 894 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 324 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2008 | 31 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 104 | 0.080 |
Why?
|
| Urothelium | 1 | 2008 | 55 | 0.080 |
Why?
|
| Cervix Uteri | 1 | 2008 | 27 | 0.080 |
Why?
|
| Hyperplasia | 3 | 2014 | 38 | 0.080 |
Why?
|
| Adenoma | 1 | 2008 | 35 | 0.080 |
Why?
|
| Fibrosis | 1 | 2008 | 118 | 0.080 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2007 | 8 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2013 | 167 | 0.080 |
Why?
|
| Administration, Intravaginal | 1 | 2007 | 8 | 0.080 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2007 | 5 | 0.080 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2008 | 56 | 0.080 |
Why?
|
| Epidermis | 1 | 2007 | 30 | 0.080 |
Why?
|
| Keratins | 1 | 2007 | 39 | 0.080 |
Why?
|
| Leptin | 2 | 2020 | 71 | 0.080 |
Why?
|
| Depression | 1 | 2011 | 443 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 448 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2007 | 57 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2008 | 182 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 725 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2013 | 765 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2011 | 1435 | 0.060 |
Why?
|
| Liver | 1 | 2008 | 483 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2009 | 922 | 0.060 |
Why?
|
| Aging | 2 | 2009 | 945 | 0.060 |
Why?
|
| Alternative Splicing | 2 | 2015 | 30 | 0.060 |
Why?
|
| Genes, ras | 2 | 2015 | 25 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2017 | 81 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 20 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 2607 | 0.060 |
Why?
|
| Adolescent | 3 | 2019 | 3515 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2011 | 3315 | 0.060 |
Why?
|
| Phenotype | 2 | 2016 | 631 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2008 | 2282 | 0.050 |
Why?
|
| Lipids | 2 | 2016 | 229 | 0.050 |
Why?
|
| Cell Movement | 2 | 2012 | 169 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2014 | 11 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1516 | 0.050 |
Why?
|
| Insulin | 2 | 2014 | 366 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2019 | 16 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2019 | 47 | 0.040 |
Why?
|
| Disease Progression | 2 | 2015 | 591 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2019 | 6 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2019 | 16 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2019 | 33 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2019 | 46 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 80 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2018 | 2 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2018 | 7 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2018 | 16 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 106 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 97 | 0.040 |
Why?
|
| Micronucleus Tests | 1 | 2018 | 4 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2018 | 81 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2018 | 42 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 23 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 82 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2018 | 84 | 0.040 |
Why?
|
| Thorax | 1 | 2018 | 29 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 100 | 0.040 |
Why?
|
| Lung Injury | 1 | 2018 | 67 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 216 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 157 | 0.030 |
Why?
|
| Bone Density | 1 | 2018 | 203 | 0.030 |
Why?
|
| Microglia | 1 | 2016 | 57 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 833 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2014 | 13 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2015 | 31 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 88 | 0.030 |
Why?
|
| Dogs | 1 | 2015 | 120 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 91 | 0.030 |
Why?
|
| Erythrocebus patas | 1 | 2014 | 1 | 0.030 |
Why?
|
| Codon | 1 | 2014 | 9 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2014 | 17 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 42 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2014 | 123 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2013 | 6 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 225 | 0.030 |
Why?
|
| Brain Death | 1 | 2013 | 27 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 47 | 0.030 |
Why?
|
| Species Specificity | 1 | 2013 | 89 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2013 | 6 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 594 | 0.030 |
Why?
|
| bcl-Associated Death Protein | 1 | 2013 | 7 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 16 | 0.030 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2013 | 3 | 0.030 |
Why?
|
| RANK Ligand | 1 | 2013 | 4 | 0.030 |
Why?
|
| Pituitary-Adrenal System | 1 | 2013 | 21 | 0.030 |
Why?
|
| Propanolamines | 1 | 2013 | 11 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 918 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2013 | 23 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2013 | 31 | 0.030 |
Why?
|
| Thyroid Hormone Receptors alpha | 1 | 2012 | 1 | 0.030 |
Why?
|
| Thyroid Hormone Receptors beta | 1 | 2012 | 2 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 28 | 0.030 |
Why?
|
| Animal Experimentation | 1 | 2012 | 5 | 0.030 |
Why?
|
| Epinephrine | 1 | 2013 | 40 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 61 | 0.030 |
Why?
|
| Swine | 1 | 2013 | 215 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 72 | 0.030 |
Why?
|
| Protein Transport | 1 | 2012 | 74 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2013 | 71 | 0.030 |
Why?
|
| Proteinuria | 1 | 2013 | 59 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 122 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 410 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2013 | 152 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 125 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2013 | 49 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2013 | 74 | 0.030 |
Why?
|
| Diet, Atherogenic | 1 | 2012 | 61 | 0.030 |
Why?
|
| Cholecalciferol | 1 | 2012 | 20 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2013 | 155 | 0.030 |
Why?
|
| Oxygen | 1 | 2013 | 142 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 146 | 0.030 |
Why?
|
| Creatinine | 1 | 2013 | 195 | 0.030 |
Why?
|
| Social Isolation | 1 | 2012 | 43 | 0.030 |
Why?
|
| Base Sequence | 1 | 2012 | 251 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 692 | 0.030 |
Why?
|
| Macaca | 1 | 2012 | 24 | 0.030 |
Why?
|
| Haplorhini | 1 | 2012 | 66 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2013 | 290 | 0.030 |
Why?
|
| Energy Intake | 1 | 2012 | 128 | 0.030 |
Why?
|
| Histological Techniques | 1 | 2011 | 6 | 0.030 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2011 | 15 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2011 | 28 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 259 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2016 | 632 | 0.020 |
Why?
|
| Lung | 1 | 2013 | 245 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 488 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 194 | 0.020 |
Why?
|
| Cholesterol | 1 | 2013 | 251 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2012 | 155 | 0.020 |
Why?
|
| Papilloma | 1 | 2010 | 8 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 885 | 0.020 |
Why?
|
| Phylogeny | 1 | 2010 | 55 | 0.020 |
Why?
|
| Foot | 1 | 2010 | 39 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 23 | 0.020 |
Why?
|
| Phosphopeptides | 1 | 2010 | 3 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 33 | 0.020 |
Why?
|
| Hand | 1 | 2010 | 66 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2010 | 47 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2010 | 80 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 62 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 99 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2010 | 92 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 60 | 0.020 |
Why?
|
| Fructosamine | 1 | 2009 | 5 | 0.020 |
Why?
|
| Animal Feed | 1 | 2009 | 16 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 247 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 834 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 201 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 227 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 228 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 125 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 289 | 0.020 |
Why?
|
| Myositis | 1 | 2009 | 10 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2009 | 45 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2009 | 42 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 543 | 0.020 |
Why?
|
| Medroxyprogesterone | 1 | 2008 | 14 | 0.020 |
Why?
|
| Ovarian Follicle | 1 | 2009 | 29 | 0.020 |
Why?
|
| Vacuoles | 1 | 2008 | 3 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 2008 | 7 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 13 | 0.020 |
Why?
|
| Kidney | 1 | 2013 | 515 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2008 | 26 | 0.020 |
Why?
|
| Chromans | 1 | 2008 | 5 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2008 | 60 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 47 | 0.020 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2007 | 4 | 0.020 |
Why?
|
| Rabbits | 1 | 2008 | 196 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2007 | 29 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 208 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 628 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 745 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 766 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 1324 | 0.020 |
Why?
|